Beam Therapeutics Inc. (BEAM)

Market Cap	2.73B +32.2%
Revenue (ttm)	55.70M -84.1%
Net Income	-414.64M
EPS	-4.42
Shares Out	98.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	430,227
Open	27.50
Previous Close	27.49
Day's Range	27.22 - 28.26
52-Week Range	13.53 - 36.44
Beta	2.13
Analysts	Buy
Price Target	46.00 (+66.43%)
Earnings Date	Feb 27, 2026

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2020
• Employees: 510
• Stock Exchange: NASDAQ
• Ticker Symbol: BEAM
• Website: https://beamtx.com

Financial Performance

In 2024, Beam Therapeutics's revenue was $63.52 million, a decrease of -83.18% compared to the previous year's $377.71 million. Losses were -$376.74 million, 184.3% more than in 2023.

Analyst Summary

According to 14 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price target is $46.0, which is an increase of 66.43% from the latest price.

Price Target

$46.0

(66.43% upside)

Analyst Consensus: Buy